Q3 FY2022 (April 1 to December 31, 2022) Conference Call

Sumitomo Pharma Co., Ltd.

January 31, 2023

Sumitomo Pharma
Innovation today, healthier tomorrows

Disclaimer Regarding Forward-looking Statements

This material contains forecasts, projections, goals, plans, and other forward-looking statements regarding the Group's financial results and other data. Such forward-looking statements are based on the Company's assumptions, estimates, outlook, and other judgments made in light of information available at the time of preparation of such statements and involve both known and unknown risks and uncertainties. Accordingly, forecasts, plans, goals, and other statements may not be realized as described, and actual financial results, success/failure or progress of development, and other projections may differ materially from those presented herein. Information concerning pharmaceuticals and medical devices (including compounds under development) contained herein is not intended as advertising or as medical advice.

Myovant Sciences Ltd. ("Myovant") is listed on the New York Stock Exchange, and the Group beneficially owns approximately 52% of the outstanding shares of Myovant. ORGOVYX® (relugolix), MYFEMBREE®/RYEQO® (relugolix combination tablet) are owned by Myovant. This material contains information about Myovant, which is based on information disclosed by Myovant. For more information on Myovant, please visit https://www.myovant.com.

Additional Information and Where to Find It

This material may be deemed to be solicitation material in respect of the proposed acquisition of Myovant by Sumitovant and Sumitomo Pharma. In connection with the proposed acquisition, Sumitovant, Sumitomo Pharma and Myovant have filed relevant materials with the SEC, including amended Schedule 13D filings and a transaction statement on Schedule 13E-3 with respect to Sumitovant and Sumitomo Pharma and a proxy statement on Schedule 14A with respect to Myovant. The definitive proxy statement and Schedule 13E-3 transaction statement have been sent to Myovant's shareholders and contain important information about the proposed transaction and related matters. SHAREHOLDERS OF MYOVANT ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH THE SEC, INCLUDING SUMITOVANT'S AND SUMITOMO PHARMA'S TRANSACTION STATEMENT ON SCHEDULE 13E-3 AND ANY AMENDMENTS OR SUPPLEMENTS THERETO, MYOVANT'S DEFINITIVE PROXY STATEMENT, AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security holders can obtain the documents free of charge at the SEC's web site, http://www.sec.gov, and Myovant shareholders can obtain free copies of the proxy statement and Schedule 13E-3 through the Investor Relations page of Myovant's website, https://www.myovant.com.

Participants in the Solicitation

Sumitomo Pharma and its directors and executive officers, and Myovant and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the holders of Myovant common stock in respect of the proposed transaction. Information about the directors and executive officers of Sumitomo Pharma is set forth in the Schedule 13E-3 transaction statement, which was filed with the SEC on January 23, 2023, and information about the directors and executive officers of Myovant is set forth in the definitive proxy statement, which was filed with the SEC on January 23, 2023. Investors may obtain additional information regarding the interest of such participants by reading the proxy statement regarding the acquisition when it becomes available.

Financial Results for Q3 FY2022

Financial Results for Q3 FY2022 (Core Basis)

Billions of yen

	Q3YTD FY2021 Results	Q3YTD FY2022 Results	Change			FY2022	
			Value	FX impact	%	Oct.31 forecasts	%
Revenue	432.1	**460.3**	28.2	56.0	6.5	604.0	76.2
Cost of sales	117.8	**139.7**	21.9	17.6	18.6	182.0	76.8
Gross profit	314.2	**320.5**	6.3	38.4	2.0	422.0	76.0
SG&A expenses	188.6	**227.5**	38.9	31.9	20.6	312.0	72.9
R&D expenses	67.8	**74.9**	7.1	9.8	10.4	100.0	74.9
Other operating income/expenses	1.1	**※ 24.8**	23.6	4.6	—	22.0	112.5
Core operating profit	59.0	**42.9**	(16.0)	1.3	(27.2)	32.0	134.1
Changes in fair value of contingent consideration (negative number indicates loss)	(0.2)	**1.2**	1.5			1.0	
Other non-recurring items (negative number indicates loss)	(0.5)	**(61.9)**	(61.4)			(63.0)	
Operating profit	58.2	**(17.8)**	(76.0)		—	(30.0)	—
Finance income/costs	7.4	**20.0**	12.6				
Profit before taxes	65.6	**2.2**	(63.4)		(96.7)		
Income tax expenses	30.4	**34.8**	4.4				
Net profit	35.2	**(32.6)**	(67.8)		—		
Net profit attributable to owners of the parent	46.4	**(18.5)**	(64.9)		—	(15.0)	—

Average rates:
Q3FY2021 Results : 1US$ = ¥111.14, 1RMB = ¥17.26
Q3FY2022 Results : 1US$ = ¥136.51, 1RMB = ¥19.88
FY2022 forecasts : 1US$ = ¥140.00, 1RMB = ¥20.00

Period end rates:
As of the end of March 2022 : 1US$ = ¥122.41, 1RMB = ¥19.26
As of the end of December 2022 : 1US$ = ¥132.71, 1RMB = ¥19.02

Revised full-year forecasts (See P.11)

(Ref.) Earnings related to Sumitovant

Billions of yen

	Q3 FY21	Q3 FY22
Revenue	**25.1**	**67.0**
SG&A expenses ＊	65.3	97.3
R&D expenses	17.5	22.9
Core operating profit	**(62.5)**	**(59.0)**
Operating profit	**(62.5)**	**(59.1)**
Net profit	(63.4)	(69.4)
Net profit attributable to owners of the parent	**(52.2)**	**(55.2)**

The figures include intra-group transaction

＊Include amortization of patent rights

※ Breakdown of other operating income/ expenses
① Sale of Priority Review Voucher
② Divestiture of BROVANA® and XOPENEX HFA®
③ Divestiture of LUNESTA®

Sumitomo Pharma

Revenue of Major Products in Japan

Billions of yen

	Q3 YTD FY2021 Results	Q3 YTD FY2022 Results	Change		FY2022	
			Value	%	Oct. 31 forecasts	%
Equa®/EquMet®	29.4	**27.3**	(2.2)	(7.3)	34.9	78.1
Trulicity® *	25.8	**24.8**	(1.0)	(3.7)	23.8	104.2
TRERIEF®	12.9	**13.1**	0.2	1.5	17.0	77.0
LATUDA®	5.0	**7.3**	2.2	44.2	9.9	73.2
METGLUCO®	6.3	**6.0**	(0.3)	(4.8)	7.8	76.8
LONASEN® Tape	1.5	**2.2**	0.7	45.2	2.7	82.9
TWYMEEG®	0.1	**1.3**	1.2	—	1.5	84.9
AG products	7.5	**7.1**	(0.4)	(5.1)	9.7	72.9
Others	28.7	**13.2**	(15.4)	(53.9)	18.5	71.4
Total	117.2	**102.2**	(15.0)	(12.8)	125.8	81.2

Note: Sales of each product are shown by invoice price (* Trulicity® is shown by NHI price)

- Sales of Trulicity® terminated at the end of December 2022
- Prescription days limit of TWYMEEG® was lifted in September 2022
- Sale of REPLAGAL® included in "Others" decreased (Q3 YTD FY2021: ¥10.7B)
- NHI price revision affected (¥9.5B) the Japan segment total

Sumitomo Pharma

Revenue of Major Products in North America & China

	Q3 YTD FY2021 Resuts	Q3 YTD FY2022 Results	Change	Q3 YTD FY2021 Resuts	Q3 YTD FY2022 Results	Change			FY2022		
						Value	FX impact	%	Oct. 31 forecasts		Yen-basis %
North America	Million $			Billions of yen					Million $	Billions of yen	
LATUDA®	1,413	1,313	(100)	157.1	179.3	22.2	33.3	14.1	1,726	241.6	74.2
APTIOM®	186	191	4	20.7	26.0	5.3	4.8	25.6	255	35.7	72.9
RETHYMIC®	—	22	22	—	3.0	3.0	0.6	—	46	6.4	46.6
BROVANA®	103	21	(83)	11.5	2.8	(8.7)	0.5	(75.5)	24	3.4	82.6
KYNMOBI®	4	2	(1)	0.4	0.3	(0.1)	0.1	(19.8)	3	0.4	80.3
ORGOVYX®	54	128	75	6.0	17.5	11.5	3.2	193.8	677	94.8	71.7
MYFEMBREE®	8	21	13	0.5	2.9	2.4	0.5	521.8			
GEMTESA®	38	125	87	4.2	17.0	12.8	3.2	303.6			
Others *	449	224	(225)	50.4	30.6	(19.8)	5.7	(39.3)			
Total	2,256	2,046	(209)	250.7	279.4	28.7	51.9	11.4	2,731	382.3	73.1
China	Million RMB			Billions of yen					Million RMB	Billions of yen	
MEROPEN®	1,226	1,167	(60)	21.2	23.2	2.0	3.1	9.6	1,290	25.8	89.9
Others	339	404	65	5.9	8.0	2.2	1.1	37.2	570	11.4	70.5
Total	1,566	1,571	5	27.0	31.2	4.2	4.1	15.6	1,860	37.2	83.9

- **North America segment**
  Revenue increased due to the impact of fluctuations in FX rates and products of Sumitovant and its subsidiaries
- Sales price of LATUDA® declined due to change in payer-mix
- BROVANA® revenue decreased due to loss of exclusivity in June 2021
- Revenue from license agreements noted in “Others” decreased (See the breakdown below the table)
- **China segment**
  Volume-Based Procurement for MEROPEN® started in November 2022

* Lump-sum revenue included in “Others”

Q3 YTD FY2021	Revenue from the alliance with Otsuka of $270M	Q3 YTD FY2022	Revenue from the license agreement for ORGOVYX® of $50M
			Milestone revenue from approval of endometriosis of $34M

FX rates:
Q3FY2021 Results : 1US$ = ¥111.14, 1RMB = ¥17.26
Q3FY2022 Results : 1US$ = ¥136.51, 1RMB = ¥19.88
FY2022 forecasts : 1US$ = ¥140.00, 1RMB = ¥20.00

Segment Information (Core Basis)

Billions of yen

		Pharmaceuticals Business					Other Business	Total
		Japan	North America	China	Other Regions	Subtotal		
Q3 YTD FY2022 Results	Revenue (Sales to customers)	102.2	279.4	31.2	13.5	426.3	34.0	460.3
	Cost of sales	54.2	49.1	6.0	3.7	113.0	26.7	139.7
	Gross profit	48.1	230.2	25.2	9.8	313.3	7.2	320.5
	SG&A expenses	38.5	174.6	8.9	1.2	223.1	4.4	227.5
	Core segment profit	9.6	55.7	16.3	8.6	90.2	2.9	93.0
	R&D expenses					72.9	1.9	74.9
	Core operating profit					42.0	1.0	42.9
Q3 YTD FY2021 Results	Revenue (Sales to customers)	117.2	250.7	27.0	7.3	402.2	29.9	432.1
	Cost of sales	61.9	23.6	5.3	4.0	94.8	23.0	117.8
	Gross profit	55.3	227.1	21.8	3.3	307.5	6.8	314.2
	SG&A expenses	38.3	135.6	8.8	1.9	184.7	4.0	188.6
	Core segment profit	17.0	91.5	12.9	1.4	122.8	2.8	125.6
	R&D expenses					67.2	0.6	67.8
	Core operating profit					56.7	2.2	59.0
Change	Revenue (Sales to customers)	(15.0)	28.7	4.2	6.2	24.1	4.1	28.2
	SG&A expenses	0.1	38.9	0.1	(0.7)	38.5	0.4	38.9
	Core segment profit	(7.4)	(35.8)	3.4	7.2	(32.6)	0.1	(32.6)
	R&D expenses					5.7	1.3	7.1
	Core operating profit					(14.8)	(1.2)	(16.0)

- **Japan:** Lower profit due to decline in sales as a result of NHI price revision
- **North America:** Profit decreased since the impact of higher expenses in Sumitovant Group and forex situation exceeded increased revenue
- **China:** Profit increased mainly due to higher revenue
- **Other Regions:** Profit includes the revenue of $50M from the license agreement for DSP-0187

Marketing Status of ORGOVYX®

- Approx. 4,000 new patients started treatment with ORGOVYX® in Q3 FY2022 (18% growth vs. Q2 FY2022)



Estimated Cumulative Patients Treated with ORGOVYX®

- Prescribed to approx. 26,000 patients since launch
- ORGOVYX® is the leading GnRH antagonist therapy for advanced prostate cancer with a 59% share based on months of therapy
- Since launch, ORGOVYX® prescriptions drove an approx. 2.6 times increase in the size of the GnRH antagonist segment for products for the treatment of advanced prostate cancer

Source: Public filings of Myovant Sciences Ltd. for Third Fiscal Quarter 2022

Marketing Status of MYFEMBREE®

- Approx. 4,500 new patients started treatment with MYFEMBREE® in Q3 FY2022 (50% growth vs. Q2 FY2022)



Estimated Cumulative Patients Treated with MYFEMBREE®

Source: Public filings of Myovant Sciences Ltd. for Third Fiscal Quarter 2022

- Prescribed to approx. 13,500 patients since launch
- Obtained 38% new-to-brand prescription (NBRx) share among GnRH antagonists therapies for uterine fibroids and endometriosis as of the end of Dec. 2022
- In January, 2023, safety and efficacy data from the 2-year long-term LIBERTY randomized withdrawal study for uterine fibroids submitted to the FDA was added on MYFEMBREE®'s U.S. Prescribing Information and will be used for promotion

Marketing Status of GEMTESA®

- Prescribed 57,491 TRx in Dec. 2022, which is greater than our FY2022 forecast

	GEMTESA®	
	Sep. 2022	Dec. 2022
TRx Share in Beta 3	11.3%	13.3%
Monthly TRx numbers	47,492	57,491

- Coverage of Medicare Part D lives has significantly expanded compared to Sep. 2022

  Coverage progress as planned for FY2022 forecast

	GEMTESA®	
	Sep. 2022	Jan. 2023
All of commercial lives（Approx. 180 million）	55%	55%
All of Medicare Part D lives（Approx. 48 million）	30%	80%

- From Jan. 2023, TV advertising covering major markets, physicians, and patients has been launched to drive product awareness and popularize the product

Financial Forecasts for FY2022

Financial Forecasts for FY2022 (Core Basis)

Billions of yen

	FY2022 Oct. 31 Forecasts	FY2022 Revised Forecasts	Change from Previous forecasts	
			Value	FX impact
Revenue	604.0	**563.0**	(41.0)	(13.7)
Cost of sales	182.0	**173.0**	(9.0)	(5.0)
Gross profit	422.0	**390.0**	(32.0)	(8.7)
SG&A expenses	312.0	**308.0**	(4.0)	(8.3)
R&D expenses	100.0	**98.0**	(2.0)	(2.5)
Other operating income and expenses (Core basis)	22.0	**50.0**	28.0	(0.9)
Core operating profit	32.0	**34.0**	2.0	1.1
Changes in fair value of contingent consideration (negative number indicates loss)	1.0	**1.0**	—	
Other non-recurring item (negative number indicates loss)	(63.0)	**(62.0)**	1.0	
Operating profit	(30.0)	**(27.0)**	3.0	
Net profit attributable to owners of the parent	(15.0)	**(35.0)**	(20.0)	
R O E (%)	(2.4)	**(6.6)**		
R O I C (%)	(1.0)	**(0.6)**		

FX rates:
FY2022 Previous forecasts : 1US$ = ¥140.00, 1RMB = ¥20.00
Revised forecasts : 1US$ = ¥135.00, 1RMB = ¥19.50

- **Revenue:** Revised down by ¥41.0B
  (FX rate impact (¥13.7B))
  (excluding FX rate impact)
  Japan +¥0.3B
  North America (¥29.1B)
  China +¥1.4B
- **SG&A expenses and R&D expenses:** FX rate impact (¥10.8B). Incorporates the expenses associated with owning 100% of Myovant
- **Other operating income and expenses (Core basis):** In addition to the sale of Priority Review Voucher, the divestiture of BROVANA®, XOPENEX HFA®, and LUNESTA® recorded up to Q3, gains on the transfer of shares of Sumitomo Pharma Food & Chemical have been factored in
- **Other non-recurring item:** Impairment loss on KYNMOBI® recorded in Q2, etc.

Financial Forecasts for FY2022

Segment Information (Core Basis)

Billions of yen

		Pharmaceuticals Business					Other Business	Total
		Japan	North America	China	Other Regions	Subtotal		
FY2022 Revised Forecasts	Revenue (Sales to customers)	126.1	340.6	37.6	17.0	521.3	41.7	563.0
	Cost of sales	65.9	61.0	7.9	5.7	140.5	32.5	173.0
	Gross profit	60.2	279.6	29.7	11.3	380.8	9.2	390.0
	SG&A expenses	52.1	235.6	11.5	1.8	301.0	7.0	308.0
	Core segment profit	8.1	44.0	18.2	9.5	79.8	2.2	82.0
	R&D expenses					95.4	2.6	98.0
	Core operating profit					8.9	25.1	34.0
FY2022 Oct. 31 Forecasts	Revenue (Sales to customers)	125.8	382.3	37.2	17.0	562.3	41.7	604.0
	Cost of sales	66.1	69.9	7.9	5.6	149.5	32.5	182.0
	Gross profit	59.7	312.4	29.3	11.4	412.8	9.2	422.0
	SG&A expenses	53.0	239.0	11.9	1.9	305.8	6.2	312.0
	Core segment profit	6.7	73.4	17.4	9.5	107.0	3.0	110.0
	R&D expenses					97.4	2.6	100.0
	Core operating profit					31.6	0.4	32.0
Change	Revenue (Sales to customers)	0.3	(41.7)	0.4	0.0	(41.0)	0.0	(41.0)
	SG&A expenses	(0.9)	(3.4)	(0.4)	(0.1)	(4.8)	0.8	(4.0)
	Core segment profit	1.4	(29.4)	0.8	0.0	(27.2)	(0.8)	(28.0)
	R&D expenses					(2.0)	0.0	(2.0)
	Core operating profit					(22.7)	24.7	2.0

- **Japan:** Profit increase expected due to decrease in SG&A expenses
- **North America:** Decrease in profit due to lower sales of LATUDA®, etc. and incorporation of expenses associated with owning 100% of Myovant
- **China:** Revised to increase MEROPEN® sales
- **Other Business:** Gains on the transfer of shares of Sumitomo Pharma Food & Chemical have been factored in Core operating profit

Research and Development

Research and Development

Development Pipeline (as of January 31, 2023)

: Psychiatry & Neurology : Oncology : Regenerative medicine / Cell therapy : Others : Frontier business Revisions since the announcement of October 2022 are shown in red

Area	Phase 1		Phase 2	Phase 3	NDA submitted
Japan	**DSP-9632P** (Levodopa-induced dyskinesia in Parkinson's disease) **DSP-0187** (Narcolepsy) **DSP-0378** (Dravet syndrome, Lennox–Gastaut syndrome)	**TP-3654** (Myelofibrosis) **DSP-5336** (Acute leukemia) **DSP-0390** (Glioblastoma)	**EPI-589** (ALS/Investigator-initiated study) **Allo iPS cell-derived products** (Parkinson's disease/ Investigator-initiated study)	**ulotaront (SEP-363856)** (Schizophrenia) **ulotaront (SEP-363856)** (Generalized anxiety disorder)* **SEP-4199** (Bipolar I depression)	
U.S.	**SEP-378608** (Bipolar disorder) **DSP-3905** (Neuropathic pain) **SEP-378614** (To be determined) **SEP-380135** (To be determined) **DSP-0038** (Alzheimer's disease psychosis) **DSP-3456 (Treatment resistant depression)**	**TP-3654** (Myelofibrosis) **DSP-5336** (Acute leukemia) **DSP-0390** (Glioblastoma) **TP-1287** (Solid tumors) **TP-1454** (Solid tumors) **KSP-1007** (Complicated urinary tract infections, Complicated intra-abdominal infections)	**EPI-589** (Parkinson's disease/ALS) **ulotaront (SEP-363856)** (Parkinson's disease psychosis) **rodatristat ethyl** (Pulmonary arterial hypertension) **URO-902** (Overactive bladder)	**ulotaront (SEP-363856)** (Schizophrenia) **ulotaront (SEP-363856)** (Adjunctive major depressive disorder)* **ulotaront (SEP-363856)** (Generalized anxiety disorder)* **SEP-4199** (Bipolar I depression) **GEMTESA® (vibegron)** (New indication: OAB in men with BPH)	
China				**ulotaront (SEP-363856)** (Schizophrenia)	**lefamulin** (Bacterial community-acquired pneumonia)

*Phase 2/3 study

Sumitomo Pharma

Clinical Development Status (Major Changes since October 31, 2022)

ulotaront

U.S. and Japan: Initiating Phase 2/3 study for Generalized Anxiety Disorder (GAD) (Co-development with Otsuka)

(Reference)
Overview of the study of ulotaront for GAD
Clinical program lead: Sunovion/Sumitomo Pharma

➢ Study design:

Patients	Adults between 18-65 years of age with generalized anxiety disorder
Arms	• ulotaront • placebo
Primary endpoint	Change from baseline to week 8 in HAM-A total score

LATUDA® (lurasidone HCl)

China: Discontinued development for bipolar I depression (Phase 3 study)

DSP-0509（guretolimod）

U.S. and Japan: Discontinued Phase 1/2 study for solid tumors. Development strategy under consideration

- Decided to discontinue development of DSP-7888, which was under consideration for development strategy

Main Events / Targets for FY2022 (as of January 31, 2023)

✓ Completed action / target Revisions since the announcement of October 31, 2022 are shown in red

Psychiatry & Neurology

- ☐ ulotaront (SEP-363856) : ☑ Start clinical studies for two new indications (☑ Adjunctive major depressive disorder, ☑ Generalized anxiety disorder)
- ☐ Advance Phase 3 study in the U.S. and Phase 2/3 study in Japan and China for schizophrenia
- ☐ SEP-4199: Advance Phase 3 studies for Bipolar I depression

Oncology

- ☑ relugolix : (Europe) Obtain approval for prostate cancer
- ☐ Advance early Phase studies

Regenerative medicine / Cell therapy

- ☐ Allogeneic iPS cell-derived products（AMD: age-related macular degeneration) : Start clinical study
- ☐ Allogeneic iPS cell-derived products（Parkinson's disease) : Start clinical study in the U.S.
- ☑ Start construction of manufacturing plant in the U.S (for RETHYMIC® and allogeneic iPS cell-derived products)

Infectious Diseases

- ☐ KSP-1007（Antimicrobial resistance） : Complete Phase 1 study in the U.S.
- ☐ universal influenza vaccine, malaria vaccines : Promote joint research and development projects

Others

- ☐ relugolix : (U.S.) ☑ Obtain approval for endometriosis
  (Europe) ☑ Submit MAA for endometriosis

Frontier

- ☑ Launch products: ☑ (Japan) MELTz Neurorehabilitation device for hand/fingers
  ☑ (U.S.) VR contents for mental health (brand name: First Resort, general wellness product)
- ☐ Promoting the current themes and generating evidence data for maximizing the value of the launched products: Digital device for relieving BPSD, etc.

Appendix

＜Contents＞

Financial Results for Q3 FY2022 (Full Basis)

Billions of yen

	Q3 YTD FY2021 Results	Q3 YTD FY2022 Results	Change	
			Value	%
Revenue	432.1	460.3	28.2	6.5
Cost of sales	117.8	139.8	21.9	18.6
Gross profit	314.2	320.5	6.3	2.0
SG&A expenses	189.0	289.5	100.4	53.1
R&D expenses	67.8	76.0	8.2	12.1
Other operating income and expenses	0.8	27.2	26.4	
Operating profit	58.2	(17.8)	(76.0)	—
Finance income and costs	7.4	20.0	12.6	
Profit before taxes	65.6	2.2	(63.4)	(96.7)
Income tax expenses	30.4	34.8	4.4	
Net profit	35.2	(32.6)	(67.8)	—
Net profit attributable to owners of the parent	46.4	(18.5)	(64.9)	—

Appendix (Financial Forecasts for FY2022)

Revenue of Major Products in Japan

Billions of yen

	FY2022 Oct. 31 Forecasts	FY2022 Revised Forecasts	Change Value
Equa®/EquMet®	34.9	**34.1**	(0.8)
Trulicity® *	23.8	**24.8**	1.0
TRERIEF®	17.0	**17.0**	—
LATUDA®	9.9	**9.3**	(0.6)
METGLUCO®	7.8	**7.8**	—
LONASEN® Tape	2.7	**2.8**	0.1
TWYMEEG®	1.5	**1.8**	0.3
AG products	9.7	**9.4**	(0.3)
Others	18.5	**19.1**	0.6
Total	125.8	**126.1**	0.3

Note: Sales of each product are shown by invoice price (* Trulicity® is shown by NHI price)

- Equa®/EquMet® and LATUDA® revised downward due to the impact of the severe competitive environment
- TWYMEEG® increases

Sumitomo Pharma

Revenue of Major Products in North America & China

	FY2022 Oct. 31 Forecasts	FY2022 Revised Forecasts	Change	FY2022 Oct. 31 Forecasts	FY2022 Revised Forecasts	Change
North America	Million $			Billions of yen		
LATUDA®	1,726	1,565	(161)	241.6	211.3	(30.4)
APTIOM®	255	255	—	35.7	34.5	(1.2)
RETHYMIC®	46	35	(11)	6.4	4.8	(1.6)
BROVANA®	24	21	(3)	3.4	2.8	(0.5)
KYNMOBI®	3	3	—	0.4	0.4	—
ORGOVYX® MYFEMBREE® GEMTESA® Others	677	644	(33)	94.8	86.8	(8.0)
Total	2,731	2,523	(208)	382.3	340.6	(41.7)
China	Million RMB			Billions of yen		
MEROPEN®	1,290	1,364	74	25.8	26.6	0.8
Others	570	562	(8)	11.4	11.0	(0.4)
Total	1,860	1,926	66	37.2	37.6	0.4

■ **North America segment**

FX rate impact is (¥12.6B). LATUDA® is expected a decline in sales due to price declines from changes in the payer mix and the impact of LOE

■ **China segment**

The impact of VBP on MEROPEN® is slightly less than expected

FX rates:
FY2022 Previous forecasts : 1US$ = ¥140.00, 1RMB = ¥20.00
Revised forecasts : 1US$ = ¥135.00, 1RMB = ¥19.50

Sumitomo Pharma

Appendix (Research and Development)

Product Launch Target (as of January 31, 2023)

Revisions since the announcement of October 2022 are shown in red



: Psychiatry & Neurology
: Regenerative medicine / cell therapy
: Oncology
: Others

* Launch schedule is based on our goal pending agreement with partners

Sumitomo Pharma

Appendix (Research and Development)

Regenerative Medicine/Cell Therapy Launched Product and Development Pipeline (as of January 31, 2023)

No revisions since the announcement of October 2022

Proposed indication, etc.	Partnering	Region (planned)	Cell type	status
Pediatric congenital athymia (RETHYMIC®)	Duke University	Global	Cultured thymus tissue	**Launched in March 2022 (U.S.)**
AMD (age-related macular degeneration)	Healios RIKEN	Global	Allo iPS cell-derived retinal pigment epithelium cells	**Preparing to start clinical study (Japan)**
Parkinson's disease (Designated as a "SAKIGAKE")	Kyoto University CiRA	Global	Allo iPS cell-derived dopamine neural progenitor cells	**In progress: investigator-initiated study (Phase 1 / 2 study) (Japan)** **Preparing to start clinical study (U.S.)**
Retinitis pigmentosa	RIKEN	Global	Allo iPS cell-derived photoreceptor (3D)	**In progress: clinical research**
Spinal cord injury	Keio University Osaka National Hospital	Global	Allo iPS cell-derived neural progenitor cells	**In progress: clinical research (Sub-Acute Phase)** **In progress: pre-clinical study (Chronic Phase)**
Kidney failure	Jikei University Bios	Japan, North America	Auto/ Allo iPS cell-based induced nephron progenitor cells (organ)	**In progress: pre-clinical study**

Aim to start clinical study in FY2022

Aim to launch in FY2024 *

* Launch schedule is based on our goal pending agreement with partners

Appendix (Research and Development)

Product Launch Target (Frontier Business) (as of January 31, 2023)

Revisions since the announcement of October 2022 are shown in red

: Medical device

: Non-medical device

FY2022	FY2023	FY2024	FY2025	FY2026	FY2027 onward
	Wearable EEG meter (Certification)				Violet Light (Depression)
					Violet Light (Dementia)
MELTz® Hand Rehabilitation System (Certification) *1	Automated blood collection/ Stabilization device				Digital medical device for depression diagnosis
Digital device for relieving BPSD*2	Smart device for hard of hearing people	Violet Light (Depression)			Digital device for relieving BPSD (Approval)
First Resort™ VR contents for mental health *3	Wearable EEG meter	Violet Light (Dementia)	MELTz® Hand Rehabilitation System (Approval)	VR contents for Social Anxiety Disorder	VR business (Disease area expansion)

*1 Certified medical device named “Active extension / flexion / extension rotation exercise device” (Accepted name for medical devices), launched in September 2022 by Sumitomo Pharma

*2 Under trial sale, plan to start full-scale sales primarily by partners in FY2023 (Aikomi : our associated company)

*3 Started trial sale in November 2022 primarily by partners (BehaVR) (Profit share 50-50 with both companies after full-scale sales)

The project description varies with the product (device sales, solution business, royalties, etc.)


Sumitomo Pharma
Innovation today, healthier tomorrows